Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 24

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 24
---
 Officer in the same individual. The Board reviews its leadership structure periodically as part of its annual self-assessment process. In addition, the Board continues to monitor developments in corporate governance as well as the approaches our peers undertake. To better align the operational leadership of the Company, the Board determined that combining the Chair and Chief Executive Officer positions under the leadership of Dr. Seehra would be in the best interests of the Company and its stockholders. This determination was based on the Board’s strong belief that, as the individual with primary responsibility for managing the Company’s day-to-day operations and with extensive knowledge and understanding of the Company, combining the roles of Chair and Chief Executive Officer in Dr. Seehra creates a clear line of authority that promotes decisive and effective leadership, both 13 TABLE OF CONTENTS within and outside the Company. In making this judgment, the Board took into account its evaluation of Dr. Seehra’s performance as Chief Executive Officer and as a current member of the Board, his rapport with the other directors, his vast expertise in the pharmaceutical industry, and the strategic perspective he would bring to the role of Chair. Dr. Seehra assumed the role of Chair effective on Dr. Gordon stepping down as Chair in July 2024. The Chair is responsible for: • calling meetings of the Board; • presiding at meetings of the Board and at meetings of the stockholders; • approving Board meeting schedules and meeting agendas, in consultation with the Lead Independent Director; and • approving Board meeting materials, in consultation with the Lead Independent Director. The Board recognizes the importance of having a Board structure that will continue to promote the appropriate exercise of independent judgment by the Board. In connection with the decision to combine the roles of Chair and Chief Executive Officer under Dr. Seehra, the Board also appointed Mr. Bienaimé to serve as Lead Independent Director. The Lead Independent Director serves as a liaison between the Chief Executive Officer and the independent directors, and facilitates discussions and deliberation among the independent directors in fulfilling their oversight responsibilities for the Company. The Lead Independent Director coordinates the activities of the other independent directors and performs such other duties and responsibilities as the Board may determine. The Lead Independent Director is responsible for: • presiding at all meetings of the Board at which the Chair is not present, including executive sessions of the independent directors; • acting as liaison between the independent directors and the Chief Executive Officer and Chair; • presiding over meetings of the independent directors; • consulting with the Chair in planning and setting schedules and agendas for Board